Cyltezo

Drug Overview

CYLTEZO, containing the active ingredient Adalimumab-adbm, is a high-potency Targeted Therapy in the Gastroenterology, Rheumatology, and Dermatology fields within the Drug Class of TNF-ALPHA INHIBITORS. It is an FDA-approved Biosimilar to the reference product Humira (adalimumab), meaning it is highly similar in structure, function, and clinical performance.

• Generic Name: Adalimumab-adbm
• US Brand Names: Cyltezo
• Route of Administration: Subcutaneous (SC) Injection (Prefilled Syringe or Pen)
• FDA Approval Status: FDA-approved for the treatment of multiple chronic inflammatory conditions, including Crohn’s Disease and Ulcerative Colitis. Notably, it was the first adalimumab biosimilar to receive an Interchangeability designation, allowing for substitution at the pharmacy level in many states.

Cyltezo is a Biologic medication—a recombinant human IgG1 monoclonal antibody. In international clinical protocols, it is utilized as a “Top-Down” therapy to achieve rapid Mucosal Healing and long-term remission in patients who have failed conventional treatments like corticosteroids or 5-ASAs.

What Is It and How Does It Work? (Mechanism of Action)

The efficacy of Cyltezo in treating Crohn’s Disease and Ulcerative Colitis is due to its ability to neutralize a specific “master switch” of the immune system.

1. TNF-Alpha Neutralization

Tumor Necrosis Factor-alpha (TNF-α) is a naturally occurring cytokine involved in normal inflammatory and immune responses. In patients with IBD or RA, the body produces excessive levels of TNF-α, which drives chronic tissue destruction. Cyltezo binds specifically to soluble and transmembrane TNF-α molecules, preventing them from attaching to their receptors on the surface of immune cells.

2. Induction of Apoptosis

Beyond simple “blocking,” Cyltezo also induces the programmed cell death (apoptosis) of inflammatory cells that are expressing TNF-α on their surface. This helps to physically reduce the number of overactive immune cells infiltrating the Intestinal Epithelial Barrier.

3. Restoration of Mucosal Integrity

By shutting down the TNF-mediated inflammatory cascade, Cyltezo allows the damaged lining of the gut (in IBD) or the synovium (in RA) to undergo Mucosal Healing. This stabilizes the Intestinal Epithelial Barrier, reduces intestinal permeability (leaky gut), and helps restore a more balanced Gut Microbiome environment.

FDA-Approved Clinical Indications

Primary Gastroenterology Indications

• Crohn’s Disease (Adult & Pediatric): Treatment of moderately to severely active disease in patients age 6 and older.
• Ulcerative Colitis (Adult): Induction and maintenance of clinical remission in patients who have had an inadequate response to immunosuppressants.

Other Approved Indications

• Rheumatoid Arthritis (RA): Reducing signs and symptoms and inducing major clinical response in adults.
• Psoriatic Arthritis & Ankylosing Spondylitis: Management of chronic joint inflammation.
• Plaque Psoriasis: Treatment of moderate-to-severe chronic plaque psoriasis in adults.
• Juvenile Idiopathic Arthritis (JIA): For patients age 2 and older.
• Hidradenitis Suppurativa: Management of chronic inflammatory skin nodules.

Dosage and Administration Protocols

Cyltezo is administered via subcutaneous injection. The “Induction Phase” involves higher, more frequent doses to rapidly lower inflammation, followed by a “Maintenance Phase.”

Dosage Adjustments and Specific Populations

• Site Rotation: Injections should be rotated between the thigh and abdomen, staying at least 1 inch away from previous injection sites.
• Pediatric Use: Specifically approved for Crohn’s down to age 6. Dosing must be strictly weight-calculated.
• Elderly Patients: Use with caution due to the higher baseline risk of serious infections in the 65+ population.
• Interchangeability: As an interchangeable biosimilar, Cyltezo can be substituted for Humira by a pharmacist (depending on state law) without a new prescription from the provider.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Biosimilarity studies for Cyltezo demonstrated that there are no clinically meaningful differences in safety, purity, or potency compared to the reference product.

• Mucosal Healing in IBD: Clinical trials show that approximately 50% of IBD patients achieve endoscopic “Mucosal Healing” within the first year of therapy.
• Remission Rates: In pivotal studies, clinical remission was achieved in roughly 30% to 40% of patients with moderate-to-severe Crohn’s disease who were previously non-responsive to other treatments.
• Switching Studies: The “VOLTAIRE-X” clinical trial specifically proved that patients can be switched back and forth between Humira and Cyltezo multiple times without any loss of efficacy or increase in side effects.
• Durability: Long-term data (2023–2026) suggests that approximately 60% of patients who respond to induction therapy maintain that response through year two.

Safety Profile and Side Effects

Cyltezo carries a Black Box Warning for Serious Infections and Malignancy.

Black Box Warning

• Serious Infections: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections.
• Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers.

Common Side Effects (>10%)

• Injection Site Reactions: Redness, itching, pain, or swelling at the site.
• Upper Respiratory Infections: Sinusitis or the common cold.
• Headache: Typically mild.
• Rash: Generalized skin irritation.

Serious Adverse Events

• Hepatitis B Reactivation: Mandatory screening for HBV is required before starting.
• Demyelinating Disease: Rare reports of new-onset or worsening of Multiple Sclerosis.
• Heart Failure: May worsen pre-existing Congestive Heart Failure.
• Lupus-like Syndrome: Development of new autoantibodies.

Management Strategies

Patients must be screened for latent TB via a PPD or QuantiFERON gold test before starting. Vigilance is required regarding “Live Vaccines” (like the MMR or Yellow Fever vaccine), which should not be given while on Cyltezo.

Research Areas

Current Research Areas focus on Mucosal Immunology and “Therapeutic Drug Monitoring” (TDM).

Recent research (2024–2026) is investigating whether measuring the blood levels of Cyltezo (TDM) can allow for “Precision Dosing,” where the dose is increased or decreased based on the patient’s individual metabolism. Scientists are also exploring the impact of TNF inhibitors on the Gut Microbiome. By reducing inflammation, Cyltezo appears to allow the “good” bacteria (like Faecalibacterium prausnitzii) to return to the Intestinal Epithelial Barrier.

Other trials are evaluating “Combination Therapy” using Cyltezo alongside Small Molecule drugs like methotrexate to prevent the body from forming “anti-drug antibodies,” which can cause the biologic to stop working over time.

Disclaimer: The research regarding the use of Therapeutic Drug Monitoring (TDM) for “Precision Dosing” and the specific shifts in the gut microbiome (e.g., Faecalibacterium prausnitzii restoration) is currently in the investigative/clinical study phase and is not yet universal clinical practice.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: TB screening (mandatory), Hepatitis B screening, and a Complete Blood Count (CBC).
• Organ Function: Review liver enzymes (ALT/AST) and kidney function.
• Specialized Testing: Evaluate for any history of heart failure or neurological disorders.
• Screening: Ensure the patient is up-to-date on all “Inactivated” vaccines (e.g., Flu, Pneumonia) before starting.

Monitoring and Precautions

• Vigilance: Instruct the patient to report any fever, persistent cough, or unusual bruising immediately.
• Lifestyle: Emphasize the importance of hand hygiene and avoiding close contact with people who have active infections.
• Timing: Adherence to the “every other week” schedule is critical; missing doses increases the risk of developing antibodies against the drug.

“Do’s and Don’ts” list

• DO store Cyltezo in the refrigerator (36°F to 46°F) and protect it from light.
• DO allow the pen/syringe to reach room temperature for 15–30 minutes before injecting to reduce pain.
• DON’T use the medication if it is cloudy, discolored, or contains large particles.
• DON’T receive any “Live Vaccines” while on this therapy.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.